Connect your AI

Geron GERN 2029

2029 at other companies

CelcuityCELC

——

Jazz PharmaceuticalsJAZZ

——

Other financials

Income statement

Revenue$51.8M+30.9%

Operating income$158.0K+101%

Net income-$3.6M+81.6%

EPS (diluted)-$0.01+66.7%

Balance sheet

Cash & equivalents$48.7M-12.2%

Total debt$134.0M+10.0%

Total equity$229.1M-14.6%

Total assets$534.1M-5.0%

Cash flow

Operating cash flow-$62.9M-31.1%

CapEx$206.0K+2.0%

Free cash flow-$43.8M-6.8%

Valuation

Market cap$878.88M-8.6%

Enterprise value$964.15M-6.2%

P/S4.7×-172×

Profitability

Operating margin-705.5%-351pp

Net margin-682.5%-339pp

FCF margin-734.4%-365pp

Returns & leverage

Return on equity-27.1%-7.8pp

Debt / equity0.6×+0.1×

Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Geron's 2029?: Geron (GERN) reported 2029 of $134.97M in Q1 2026.